Effect of Virtual Reality Glasses in The Arteriovenous Fistule Cannulation Processon Paın and Patient Satisfaction

April 5, 2022 updated by: Didem Lafci, Mersin University

Effect of Virtual Reality Headset Glasses Used in The Arteriovenous Fistule Cannulation Processon Paın and Patient Satisfaction

This research was conducted as a randomized controlled experimental study aiming to determine the impact of virtual reality glasses used in the AVF process on the pain felt by patients and patient satisfaction.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Chronic kidney disease (CKD) is a progressive, irreversible renal disease in which the ability of the body to maintain the balance of metabolism, fluid and electrolytes fails. Chronic kidney disease (CKD) is one of the major health problems with an increasing prevalence in the World. Hemodialysis as one of the most common methods of renal replacement therapy is a stressful procedure despite to maintain the survival of patients with chronic kidney disease that permanent and safe vascular access is one of the requirements of a successful hemodialysis. The pain of AVF puncture is common among the patients undergoing HD as acute and chronic pain which reported in more than 82% and 92% of them, respectively. Experience of the arteriovenous fistula puncture-related pain can have unpleasant effects on the patients, it causes that hemodialysis patients experience more disability, depression, irritability, and insomnia than other patients in adapting to stress. Experiencing continued pain can also affect the level of hemodialysis acceptance in patients and ultimately decrease quality of life. Therefore, pain control is an important priority in these patients.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Mersin, Turkey, 33110
        • Mersin University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Receiving HD treatment
  • Open to communication
  • Fully oriented
  • Without vision, hearing and perception problems
  • Without any psychiatric illness
  • Without a history of seizures such as epilepsy
  • HD treatment administered via AVF
  • İn the last day, no injection was made into any artery or vein from the place where the intervention will be performed
  • Without any signs of infection such as redness, swelling, open wound in the area where the intervention will be performed
  • Standardized Mini Mental Test value is 24 points and above
  • One-time needle attempt from AV

Exclusion Criteria:

  • Refusing to participate in the study
  • under the age of 18
  • Can't speak Turkish
  • Closed to communication and not fully oriented
  • Visual, hearing and perception problems
  • Any psychiatric illness
  • Having a history of seizures such as epilepsy
  • HD treatment not administered via AVF
  • Injection into any artery or vein from the place where the intervention will be performed in the last day,
  • Any signs of infection such as redness, swelling, open wound in the area to be operated
  • Using any pain medication before the procedure on the same day
  • SMMT value below 24 in patients over 65 years of age
  • Cannulation procedure not performed with a 16 G AVF needle
  • Patients with multiple injections from the AVF

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Virtual Reality Glasses Group
The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure. After the AVF cannulation procedure was completed and 10 minutes later, the VAS and Hemodynamic Variables Follow-up Form were reapplied, and the 2nd and 3rd measurements were obtained. Patients' satisfaction was measured with VAS 10 minutes after the procedure. During the application of virtual reality glasses, a screen was pulled between the patients in the intervention and control groups so that there would be no interaction.
The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
NO_INTERVENTION: Control group
Without any application to the patients in the control group, the AVF cannulation procedure before HD was performed with the constant site-area puncture technique used by the clinic (after the patient was placed in the fowler position, the arterial needle was 3 cm away from the anastomosis at an angle of 20°-45° towards the distal, and the venous needle was from the arterial needle. 3-5 cm more proximal, again at an angle of 20°-45°) was performed by the HD nurse. The 1st, 2nd and 3rd measurements were obtained as in the intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain evaluated using the Visual Analog Scale
Time Frame: Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
The patient marks a value between 1 and 10 on the Visual Analog Scale (VAS). As the value increases, the severity of pain increases.
Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
systolic blood pressure (SBP), diastolic blood pressure (DBP), mmHg
Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
Heart rate
Time Frame: Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
beats per minute
Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
respiratory rate
Time Frame: Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
ekspiration and inspiration per minute
Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
peripheral oxygen saturation
Time Frame: Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)
%, percentage of oxygenated hemoglobin in peripheral arterial blood
Change from before implementation, immediately after the procedure and after 10 minutes of practice (Virtual Reality Headset Glasses)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hatice Şen, Master, Pozantı State Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 13, 2018

Primary Completion (ACTUAL)

January 9, 2019

Study Completion (ACTUAL)

January 9, 2019

Study Registration Dates

First Submitted

March 25, 2022

First Submitted That Met QC Criteria

April 5, 2022

First Posted (ACTUAL)

April 13, 2022

Study Record Updates

Last Update Posted (ACTUAL)

April 13, 2022

Last Update Submitted That Met QC Criteria

April 5, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe